查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1988030

慢性脱髓鞘多发性神经炎市场：治疗方法、患者年龄、疾病严重程度、最终用户和通路划分－2026-2032年全球市场预测

Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment Modality, Patient Age, Disease Severity, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，慢性脱髓鞘多发性神经炎(CIDP) 市场价值将达到 26.4 亿美元，到 2026 年将成长至 28 亿美元，到 2032 年将达到 39.6 亿美元，复合年增长率为 5.97%。

主要市场统计数据
基准年 2025 26.4亿美元
预计年份：2026年 28亿美元
预测年份 2032 39.6亿美元
复合年增长率 (%) 5.97%

它简洁地组织了临床复杂性、治疗路径和策略重点，指导护理、研究和商业化领域的相关人员做出明智的决策。

慢性脱髓鞘多发性神经炎在临床、诊断和治疗方面具有独特的复杂性，需要综合分析以製定策略决策。本执行摘要整合了关于该疾病的生物学特征、诊疗路径、治疗方法和商业格局的最新知识，为临床医生、保险公司和相关人员提供简洁全面的概述。摘要阐述了不断发展的诊断标准、免疫疗法的进展以及变革性的医疗服务模式如何相互交织并影响患者预后和服务利用。

诊断技术的进步、治疗方法的创新以及医疗保健服务系统的重新设计如何汇聚在一起，重新定义治疗方法和患者管理中的价值评估。

慢性脱髓鞘多发性神经炎的治疗管理格局正在经历一场变革，这主要得益于技术进步、监管规范的完善以及患者期望的不断变化。新的诊断方法和生物标记研究正在改善病例识别和预后分层，从而实现更具针对性的治疗策略。同时，免疫球蛋白製剂和给药方法的进步，以及单株抗体和其他免疫调节剂应用经验的积累，正在拓展临床医生的选择范围，并促使人们重新评估长期治疗通讯协定。

评估关税政策对供应链、製造策略和治疗可用性的影响，并考虑其对采购和临床决策的影响。

贸易和关税政策的趋势可能对用于治疗慢性脱髓鞘多发性神经炎的疗法的生产经济性、供应链韧性和成本结构产生重大影响。原材料和成品生技药品的进口关税和监管要求的变化可能会使上游采购流程复杂化，并促使製造商重新评估其供应商网路和库存策略。同时，关税可能会改变生产的地域经济格局，并促使製造地迁移或采用双重采购安排，以减轻贸易中断的影响。

将治疗方法特征、医疗保健环境、通路、年龄层和严重程度与临床和营运决策框架联繫起来的详细細項分析。

基于细分市场的分析揭示了不同治疗方法、医疗机构、配送机制、患者年龄层和疾病严重程度类别所面临的运作和临床挑战。依治疗方法分析，治疗方案包括皮质类固醇、Azathioprine、Cyclophosphamide、Mycophenolate Mofetil和Rituximab单抗等免疫抑制剂，以及静脉注射免疫球蛋白、血浆置换和皮下注射免疫球蛋白。每种疗法都有其独特的给药需求、监测需求和安全性特征，这些因素会影响医疗机构的选择和资源分配。在此背景下，不同类型的免疫抑制剂需要专门的监测通讯协定和病患咨询，这会影响专科诊所与综合医院的用药模式。

影响治疗方案取得、报销和提供的全球主要区域的相对区域趋势和策略考量。

区域趋势影响着美洲、欧洲、中东和非洲以及亚太市场的临床实践模式、法规环境、报销框架和供应物流。在美洲，不断发展的支付模式和健全的专科医疗网络支持着以门诊输液服务和居家给药（在临床适宜的情况下）为重点。同时，生物製药和免疫疗法的监管细则正在推动给药平台的创新。相较之下，欧洲和中东及非洲部分地区的准入和报销情况存在差异，需要製定在地化的策略，并考虑国家处方药目录、集中采购和区域生产伙伴关係。

製造商和服务供应商在协调临床证据、供应物流和患者支援以实现永续成长方面面临竞争与合作的挑战。

竞争情报显示，众多机构在该治疗领域开展业务，从生产免疫球蛋白製剂的生物製药企业到提供血浆置换和家庭输液服务的专业服务供应商，不一而足。拥有临床开发专长和完善的生产及分销基础设施的公司，更有能力满足生物製药固有的复杂低温运输和品管要求。此外，投资于病患支援计画、居家照护护理师培训以及支持用药依从性的数位化工具的公司，可以提升其对支付方和医疗服务提供者的价值提案。

为高阶主管提供切实可行的策略措施，以加强证据产生、巩固供应链并推动医疗保健服务，从而维持临床和商业性的成功。

产业领导者应采取多管齐下的策略，整合临床证据的发展、供应链韧性以及相关人员的协作，以最大限度地提高治疗效果和业务永续性。首先，他们应优先创建可靠的真实世界数据 (RWE) 和开展有针对性的临床试验，以揭示长期疗效、治疗方法之间的疗效比较以及能够引起支付方共鸣的成本效益指标。其次，他们应透过多元化关键原材料来源、建立区域性生产或填充/包装能力以及协商灵活的物流安排来增强供应链韧性，从而降低关税和贸易风险。

透过透明、多方面的研究途径，结合专家访谈、系统性文献综述和迭代检验，我们得出实用的临床和操作见解。

本分析的调查方法结合了定性专家对话、严谨的原始文献回顾以及对营运和监管趋势的系统性整合。关键资讯来源包括对临床专业人员、药房负责人和医疗系统管理人员的访谈，以了解他们对治疗方法选择、静脉给药能力和患者管理的实际观点。除这些访谈外，对同行评审的临床研究、监管指南和专业学会建议的系统性回顾，确保了治疗和诊断趋势均基于检验的证据。

透过整合临床趋势、营运挑战和策略优势，我们制定了一条改善患者预后和永续医疗保健服务的道路。

本执行摘要对影响慢性脱髓鞘多发性神经炎治疗的临床、运作和策略因素进行了全面阐述。报告重点强调了向个人化免疫调节策略的转变、对居家和门诊护理模式日益重视，以及真实世界数据（REW）在支持与支付方合作方面的重要性日益凸显。分析还着重探讨了可能影响治疗方法可及性和选择的供应链因素和政策主导压力，强调了製定积极主动的紧急时应对计画和加强相关人员合作的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：慢性脱髓鞘多发性神经炎市场（依治疗方法）

  • 皮质类固醇
  • 免疫抑制剂
    • Azathioprine
    • Cyclophosphamide
    • Mycophenolate Mofetil
    • Rituximab
  • 静脉注射免疫球蛋白
  • 血浆置换
  • 皮下注射免疫球蛋白

第九章 依患者年龄分類的慢性脱髓鞘多发性神经炎市场

  • 成人版
  • 老年人
  • 儿童

第十章：慢性脱髓鞘多发性神经炎－以严重程度分類的疾病市场

  • 温和的
  • 缓和
  • 严重

第十一章：慢性脱髓鞘多发性神经炎市场：以最终用户划分

  • 居家照护
  • 医院
  • 专科诊所

第十二章：慢性脱髓鞘多发性神经炎市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：慢性脱髓鞘多发性神经炎市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章慢性脱髓鞘多发性神经炎市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：慢性脱髓鞘多发性神经炎市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国慢性脱髓鞘多发性神经炎市场

第十七章：中国慢性脱髓鞘多发性神经炎市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Avalon Pharma Pvt Ltd.
  • Baxter International, Inc.
  • Biotest AG
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • Green Cross Corporation
  • Grifols, SA
  • Johnson & Johnson Services, Inc.
  • Kedrion Biopharma
  • Lee BioSolutions
  • Merck & Co., Inc.
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
  • Zai Lab Limited
Product Code: MRR-F97DD5A7D581

The Chronic Inflammatory Demyelinating Polyneuropathy Market was valued at USD 2.64 billion in 2025 and is projected to grow to USD 2.80 billion in 2026, with a CAGR of 5.97%, reaching USD 3.96 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.64 billion
Estimated Year [2026] USD 2.80 billion
Forecast Year [2032] USD 3.96 billion
CAGR (%) 5.97%

Concise framing of clinical complexity, treatment pathways, and strategic priorities to orient stakeholders toward informed decisions across care, research, and commercialization

Chronic inflammatory demyelinating polyneuropathy presents distinct clinical, diagnostic, and therapeutic complexities that demand integrated analysis for strategic decision making. This executive summary synthesizes current understanding of disease biology, care pathways, therapeutic modalities, and the commercial environment to equip clinicians, payers, and industry stakeholders with a concise yet comprehensive briefing. It addresses how evolving diagnostic criteria, advances in immunotherapy, and shifts in care delivery intersect to influence patient journeys and service utilization.

By focusing on evidence-based treatment practices and operational realities across settings of care, the narrative connects clinical endpoints with real-world considerations such as treatment tolerability, infusion infrastructure, and the capacity of specialty clinics and home care services. Moreover, the introduction frames emerging clinical trial trends and regulatory approaches that are reshaping the competitive landscape. Ultimately, this section sets the stage for a deeper exploration of transformative shifts, tariff implications, segmentation intelligence, regional dynamics, and actionable recommendations crafted for executives and clinical leaders tasked with navigating a complex, rapidly changing field.

How diagnostic advances, treatment innovation, and care delivery redesign are converging to redefine therapeutic approaches and value assessment in patient management

The landscape for managing chronic inflammatory demyelinating polyneuropathy is undergoing transformative shifts driven by technological maturation, regulatory refinement, and evolving patient expectations. Novel diagnostics and biomarker research are improving case ascertainment and prognostic stratification, which in turn support more targeted therapeutic strategies. Concurrently, advances in the formulation and delivery of immunoglobulin therapies, alongside growing experience with monoclonal antibodies and other immunomodulatory agents, are expanding clinician options and prompting reassessment of long-term management protocols.

At the same time, health systems are adjusting care delivery models to emphasize outpatient and home-based administration where clinically appropriate. This shift is facilitated by advancements in subcutaneous immunoglobulin formulations and remote monitoring technologies, which reduce reliance on inpatient infusion centers and enhance patient convenience. Transitional dynamics also include payer scrutiny around long-term therapy value, leading to more rigorous outcomes measurement and utilization management. Collectively, these forces are accelerating a move toward personalized, value-oriented care that recognizes both clinical efficacy and system sustainability.

Assessment of tariff policy effects on supply chains, manufacturing strategies, and treatment availability with implications for procurement and clinical decision making

Policy developments in trade and tariffs can exert significant influence on manufacturing economics, supply chain resilience, and the cost structure of therapies used in chronic inflammatory demyelinating polyneuropathy care. Changes to import duties or regulatory requirements for raw materials and finished biologics may increase upstream sourcing complexity, prompting manufacturers to reassess supplier networks and inventory strategies. In parallel, tariffs can shift the geographic economics of production, encouraging relocation of manufacturing nodes or the adoption of dual-sourcing arrangements to mitigate exposure to trade disruptions.

These dynamics can cascade into downstream stakeholders: hospital pharmacies, specialty clinics, and distribution channels may face altered procurement lead times or pricing pressures that necessitate adjustments in contracting and inventory management. Clinicians and health systems may experience variability in product availability, which could influence therapeutic choices between intravenous and subcutaneous formulations where multiple options exist. Consequently, strategic planning must incorporate scenario analysis of tariff impacts on supply continuity, cost of goods, and the operational feasibility of home care versus facility-based administration, while also engaging with payers to align reimbursement models with emerging cost structures.

In-depth segmentation analysis linking therapy characteristics, care settings, distribution pathways, age cohorts, and severity gradations to clinical and operational decision frameworks

Segment-specific analysis reveals differentiated operational and clinical imperatives across treatment modalities, care settings, distribution mechanisms, patient age groups, and disease severity categories. When examined by treatment modality, the therapeutic mix spans corticosteroids, immunosuppressants - including azathioprine, cyclophosphamide, mycophenolate mofetil, and rituximab - intravenous immunoglobulin, plasma exchange, and subcutaneous immunoglobulin, each with distinct administration requirements, monitoring needs, and safety profiles that influence site selection and resource allocation. In this context, immunosuppressant subtypes demand specialized monitoring protocols and patient counseling that can shape utilization patterns in specialty clinics compared with broader hospital settings.

End-user segmentation highlights the operational tradeoffs between home care, hospitals, and specialty clinics. Home care models prioritize patient education, device compatibility, and remote monitoring, while hospitals underscore infusion capacity and acute management capabilities. Specialty clinics often serve as hubs for diagnostic clarification and initiation of long-term immunotherapy. Distribution channel differentiation across hospital pharmacy, online pharmacy, and retail pharmacy affects dispensing practices, cold chain stewardship, and patient access. Patient age segmentation into adult, geriatric, and pediatric populations underscores differing safety considerations, dosing strategies, and caregiver support needs that must be integrated into treatment planning. Disease severity segmentation - mild, moderate, and severe - further informs therapeutic sequencing, frequency of interventions, and intensity of monitoring, creating decision pathways that intersect with payer authorization and care coordination requirements.

Comparative regional dynamics and strategic considerations across major global territories shaping access, reimbursement, and delivery of therapeutic options

Regional dynamics shape clinical practice patterns, regulatory environments, reimbursement frameworks, and supply logistics across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, evolving payer models and robust specialty care networks support a focus on outpatient infusion services and home administration where clinically appropriate, while regulatory clarity around biologics and immunotherapies encourages innovation in delivery platforms. Conversely, certain jurisdictions in Europe, the Middle East, and Africa exhibit heterogeneity in access and reimbursement, prompting localized strategies that account for national formularies, centralized procurement, and regional manufacturing partnerships.

In the Asia-Pacific region, rapid growth in healthcare infrastructure and an expanding base of specialist clinicians are creating opportunities for broader access to advanced therapies, though variability in regulatory pathways and local manufacturing capacity remains a factor. Across these regions, transitions toward value-based procurement and a greater emphasis on real-world evidence are influencing formulary decisions and clinical guidelines. Therefore, market entrants and established suppliers must calibrate commercialization strategies to local regulatory, payer, and delivery realities, while also coordinating cross-regional supply chain and medical affairs efforts to ensure consistent standards of care.

Competitive and collaborative imperatives for manufacturers and service providers to align clinical evidence, supply logistics, and patient support for sustainable growth

Competitive intelligence indicates that a diverse set of organizations - from biopharmaceutical manufacturers producing immunoglobulin formulations to specialty service providers delivering plasma exchange and home infusion capabilities - are active in this therapeutic area. Firms that combine clinical development expertise with robust manufacturing and distribution infrastructures are better positioned to meet the complex cold chain and quality control demands inherent to biologic therapies. In addition, entities that invest in patient support programs, training for home care nurses, and digital adherence tools strengthen their value proposition to payers and providers.

Partnerships between pharmaceutical companies and logistics providers, as well as collaborations with academic centers for post-marketing evidence generation, are becoming more common. These alliances support lifecycle management strategies and help build the real-world datasets that payers increasingly require. Service providers that offer scalable infusion capacity and streamlined prior authorization support gain traction with clinicians seeking to minimize administrative burden. Overall, organizations that align clinical evidence generation with operational excellence and stakeholder engagement are likely to sustain competitive advantage as treatment paradigms evolve.

Practical strategic measures for executives to enhance evidence generation, fortify supply chains, and advance care delivery to sustain clinical and commercial success

Industry leaders should pursue a multipronged strategy that integrates clinical evidence development, supply chain resilience, and stakeholder engagement to maximize therapeutic impact and operational sustainability. First, prioritize generation of robust real-world evidence and targeted clinical studies that clarify long-term outcomes, comparative effectiveness across modalities, and cost-utility measures that resonate with payers. Second, strengthen supply chain resilience by diversifying sourcing of critical raw materials, establishing regional manufacturing or fill-finish capabilities, and negotiating flexible logistics arrangements to mitigate tariff and trade risks.

Third, invest in care delivery innovations that expand safe home administration and support specialty clinics through training, telehealth integration, and digital monitoring tools to improve adherence and reduce total cost of care. Fourth, engage proactively with payers and policy makers to align reimbursement pathways with clinical value, leveraging outcomes data and patient-reported measures. Finally, cultivate cross-sector partnerships - including with academic institutions and patient advocacy groups - to accelerate guideline adoption, improve patient education, and ensure equitable access across age cohorts and severity profiles. Together, these actions create a resilient commercial model grounded in clinical credibility and operational adaptability.

Transparent, multi-source research approach combining expert interviews, systematic literature review, and iterative validation to produce actionable clinical and operational insights

The research methodology underpinning this analysis combines qualitative expert engagement, rigorous review of primary literature, and structured synthesis of operational and regulatory developments. Primary inputs included consultations with clinical specialists, pharmacy leaders, and health system administrators to capture frontline perspectives on treatment selection, infusion capacity, and patient management. These interviews were complemented by a systematic review of peer-reviewed clinical studies, regulatory guidance, and professional society recommendations to ensure that therapeutic and diagnostic trends are grounded in validated evidence.

To ensure reliability, findings were triangulated across multiple sources and validated through iterative expert review. Attention was given to distinguishing established clinical practice from emerging experimental approaches, and to identifying gaps in evidence where further research is warranted. Limitations are acknowledged: regional heterogeneity in clinical guidelines and the variable quality of real-world datasets can constrain the generalizability of certain operational inferences. Nonetheless, the methodology emphasizes transparency, reproducibility, and the practical applicability of insights for decision-makers in clinical, commercial, and policy roles.

Synthesis of clinical trends, operational challenges, and strategic levers that together define the pathway to improved patient outcomes and sustainable care delivery

This executive synthesis delivers a cohesive view of the clinical, operational, and strategic forces shaping care for chronic inflammatory demyelinating polyneuropathy. It underscores a shift toward personalized immunomodulatory strategies, increasing emphasis on home and outpatient delivery models, and the rising importance of real-world evidence to support payer engagement. The analysis also highlights supply chain considerations and policy-driven pressures that can influence availability and selection of therapies, reinforcing the need for proactive contingency planning and stakeholder alignment.

In closing, effective responses require coordinated action across evidence generation, supply operations, and payer engagement to ensure that patients receive timely, appropriate care while health systems manage cost and capacity. Stakeholders who integrate clinical insight with pragmatic operational strategies will be better positioned to navigate uncertainty and to translate scientific advances into improved outcomes for patients living with this chronic neurologic condition.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment Modality

  • 8.1. Corticosteroids
  • 8.2. Immunosuppressants
    • 8.2.1. Azathioprine
    • 8.2.2. Cyclophosphamide
    • 8.2.3. Mycophenolate Mofetil
    • 8.2.4. Rituximab
  • 8.3. Intravenous Immunoglobulin
  • 8.4. Plasma Exchange
  • 8.5. Subcutaneous Immunoglobulin

9. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Patient Age

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Disease Severity

  • 10.1. Mild
  • 10.2. Moderate
  • 10.3. Severe

11. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End User

  • 11.1. Home Care
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Chronic Inflammatory Demyelinating Polyneuropathy Market

17. China Chronic Inflammatory Demyelinating Polyneuropathy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Avalon Pharma Pvt Ltd.
  • 18.6. Baxter International, Inc.
  • 18.7. Biotest AG
  • 18.8. CSL Limited
  • 18.9. F. Hoffmann-La Roche Ltd.
  • 18.10. Green Cross Corporation
  • 18.11. Grifols, S.A.
  • 18.12. Johnson & Johnson Services, Inc.
  • 18.13. Kedrion Biopharma
  • 18.14. Lee BioSolutions
  • 18.15. Merck & Co., Inc.
  • 18.16. Novartis AG
  • 18.17. Octapharma AG
  • 18.18. Pfizer Inc.
  • 18.19. Sanofi SA
  • 18.20. Takeda Pharmaceutical Company Limited
  • 18.21. Teva Pharmaceutical Industries Ltd.
  • 18.22. UCB S.A.
  • 18.23. Viatris Inc.
  • 18.24. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 161. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 166. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 167. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)